Table 2

Published studies comparing oxytocin (syntocinon) with alternative uterotonic agents

Author, citation

Study design

Exposures

Outcome measures

Results

Conclusions


Catanzarite VA et al

Am J Perinatol

1990;7:39–42.

RCT double blind

46 women

Elective CS

Oxytocin 20 IU iv bs PGF125 mcg im

After placenta delivered

ΔHCT (EBL)

No difference in EBL

No benefit with carboprost

Chou MM et al

Am J Obstet Gynecol

1994;171:1356–60.

RCT double blind

60 women

Elective CS

Oxytocin 20 IU iv vs PGF125 mcg im

EBL

ΔHCT, ΔHb

Side effects (SE)

No significant differences

No benefit with carboprost

Boucher M et al

J Perinatol

1998;18:202–7.

RCT double blind

57 women

Elective CS

Oxytocin infusion

16 hr vs

Carbetocin 100 mcg iv

EBL

Side effects

Carbetocin as effective

Lower EBL

Carbetocin as effective/reliable

Dansereau J et al

Am J Obstet Gynecol

1999;180:670–6.

RCT double blind

635 women

Elective CS

Oxytocin infusion

8 hr vs

Carbetocin 100 mcg iv

Need for additional uterotonic agent

Carbetocin more effective

10% vs 4.7%

Carbetocin more effective than infusion only

Acharya G et al

Acta Obst Gyn Scand

2001;80:245–50.

RCT single blind

60 women

Elective CS/regional

Oxytocin 10 IU iv vs

Misoprostol 400 mcg po

EBL, HCT, Hb,

Side effects

No difference

No SE

Misoprostol as safe/effective as 10 IU oxytocin

Lokugamage AU et al

Aus NZ J Obst Gyne

2001;41:411–4.

RCT double blind

40 women

Elective/Em CS

Oxytocin 10 IU iv vs

Misoprostol 400 mcg po

EBL

ΔHb

Additional uterotonic

No difference

Misoprostol an alternative to 10 IU

Need for large RCT


Murphy et al. BMC Pregnancy and Childbirth 2009 9:36   doi:10.1186/1471-2393-9-36

Open Data